FASTK and astrocytoma (excluding glioblastoma): Additionally, increased expression of FASTK in astrocytoma led to upregulated migration and invasion.These findings demonstrate that FASTK can be used as a prognostic biomarker but also as a therapeutic target [22].The other important FASTK proteins that have been implicated in tumour progression include, FASTKD2and FASTKD4, already described in the Table.